AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33900803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Chemotherapy Management Program (OCMP)
Number of subjects: 0
Study 32209975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic-biomechanical parameter (TBI)
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: PRFI-Pentacam Random Forest Index
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: BAD-D-Belin-Ambrosio D value
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: CBI-corneal biomechanical index
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: IS Abs-Inferior-superior value
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: PRFI
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: BAD-D
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: CBI
Number of subjects: 1295
Study 32209975 — intervention group
Group type: COMPARATOR
Intervention: IS Abs
Number of subjects: 1295
Study 34791107 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks)
Number of subjects: 136
Study 34791107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 136
Study 33647588 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher working memory function
Number of subjects: 86
Study 33647588 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful moments and presence of peers and alcohol cues
Number of subjects: 86
Study 33647588 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological sex differences
Number of subjects: 86
Study 33647588 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory function
Number of subjects: 86
Study 32592657 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 13981
Study 32592657 — intervention group
Group type: COMPARATOR
Intervention: Non-statin
Number of subjects: 13981
Study 34119569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (Group S)
Number of subjects: 60
Study 34119569 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia (Group D)
Number of subjects: 60
Study 32197503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-based system for monitoring rehabilitation progress after TKR
Number of subjects: 0
Study 32197503 — intervention group
Group type: COMPARATOR
Intervention: Cybex isokinetic dynamometer (control)
Number of subjects: 0
Study 33711638 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0
Study 33711638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32415792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational level of the head of household (proxy for poverty)
Number of subjects: 941
Study 32415792 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of children per room in the household
Number of subjects: 941
Study 32415792 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 941
Study 35872996 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphase prediction models developed from a retrospective cohort database
Number of subjects: 17445
Study 35872996 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based app 'OHSS monitor'
Number of subjects: 17445
Study 34651535 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Number of subjects: 44559
Study 34651535 — intervention group
Group type: COMPARATOR
Intervention: COC(LNG)
Number of subjects: 44559
Study 36205248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 45 days after hospital discharge
Number of subjects: 10000
Study 36205248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 34105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to instrumental music before bed
Number of subjects: 249
Study 34105416 — intervention group
Group type: COMPARATOR
Intervention: Listening to lyrical music before bed
Number of subjects: 249
Study 34105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent nighttime earworms
Number of subjects: 249
Study 34105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal slow oscillation activity
Number of subjects: 249
Study 32697909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast randomized iteration method for full configuration interaction (FCI‐FRI) with initiator approximation
Number of subjects: 0
Study 32697909 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistochastic extension of FCI‐FRI
Number of subjects: 0
Study 32697909 — intervention group
Group type: EXPERIMENTAL
Intervention: New approach to sampling excitations
Number of subjects: 0
Study 35646366 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-simulating eyeglasses
Number of subjects: 30
Study 35646366 — intervention group
Group type: COMPARATOR
Intervention: Sham eyeglasses
Number of subjects: 30
Study 35646366 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (non-cancer, disease-free individuals)
Number of subjects: 30
Study 35646366 — intervention group
Group type: COMPARATOR
Intervention: Positive controls (advanced cancer patients with disrupted circadian organization)
Number of subjects: 30
Study 33863853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 60
Study 33863853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bike exercise
Number of subjects: 60
Study 33863853 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WE)
Number of subjects: 60
Study 33863853 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 60
Study 33189414 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMUFRA program (multi-component exercise program, high-intensity resistance training combined with self-massage for myofascial release) for 12 weeks (2 d.wk-1)
Number of subjects: 50
Study 33189414 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMUFRA program
Number of subjects: 50
Study 34546614 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRP application onto the sutured fascia
Number of subjects: 33
Study 34546614 — intervention group
Group type: COMPARATOR
Intervention: Control (no L-PRP application)
Number of subjects: 33
Study 32304829 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention (SPI) during jail detention plus post-release phone follow-up
Number of subjects: 800
Study 32304829 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard Care
Number of subjects: 800
Study 34870852 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane sedation
Number of subjects: 66
Study 34870852 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 66
Study 33410692 — intervention group
Group type: EXPERIMENTAL
Intervention: iCIPT2 (iterative configuration interaction with selection and second-order perturbation theory)
Number of subjects: 0
Study 33410692 — intervention group
Group type: EXPERIMENTAL
Intervention: iCIPT2
Number of subjects: 0
Study 32242760 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consent process
Number of subjects: 0
Study 32242760 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive tablet 'app' consent process
Number of subjects: 0
Study 32242760 — intervention group
Group type: COMPARATOR
Intervention: Standard brochure-based consent
Number of subjects: 0
Study 34259849 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative language in physician notes
Number of subjects: 507
Study 34259849 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive language in physician notes
Number of subjects: 507
Study 33170863 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + FTC
Number of subjects: 187
Study 33170863 — intervention group
Group type: COMPARATOR
Intervention: cART
Number of subjects: 187
Study 35973906 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension
Number of subjects: 318
Study 35973906 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 318
Study 33725153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood transfusion (FWBG)
Number of subjects: 65
Study 32379992 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing Weissella cibaria CMU (1 × 10^8 CFU/g)
Number of subjects: 92
Study 32379992 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 92
Study 36476623 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dalbavancin
Number of subjects: 0
Study 36476623 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose dalbavancin
Number of subjects: 0
Study 36476623 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibiotic
Number of subjects: 0
Study 33855218 — intervention group
Group type: COMPARATOR
Intervention: Eptinezumab
Number of subjects: 45
Study 33373537 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration algorithm using higher CDRS‐R item score
Number of subjects: 439
Study 33373537 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 439
Study 33135364 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of Food Scale
Number of subjects: 67
Study 33135364 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Efficacy Lifestyle Questionnaire
Number of subjects: 67
Study 33586647 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided taVNS
Number of subjects: 82
Study 33586647 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided taVNS
Number of subjects: 82
Study 33586647 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 82
Study 33705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 204
Study 33705158 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 204
Study 32413383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 275
Study 32413383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 33808784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable diosmin (μsmin® Plus) 450 mg tablet once daily for 8 weeks
Number of subjects: 72
Study 33808784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34423374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus placebo
Number of subjects: 6835
Study 34423374 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 6835
Study 32522163 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO symptom-report system
Number of subjects: 40
Study 32522163 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO system
Number of subjects: 40
Study 35984181 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated TKA
Number of subjects: 213
Study 35984181 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 213
Study 34571263 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm (expected stay 7-10 days)
Number of subjects: 0
Study 34571263 — intervention group
Group type: COMPARATOR
Intervention: Long arm (expected stay 12-16 days)
Number of subjects: 0
Study 32867992 — intervention group
Group type: EXPERIMENTAL
Intervention: CWE (basal diet + 1,000 mg/kg chestnut tannins)
Number of subjects: 168
Study 35227777 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3)
Number of subjects: 0
Study 35227777 — intervention group
Group type: COMPARATOR
Intervention: Standard induction regimen (adalimumab 160 mg at week 0 and 80 mg at week 2)
Number of subjects: 0
Study 35227777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg every week (ew) maintenance regimen
Number of subjects: 0
Study 35227777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg every other week (eow) maintenance regimen
Number of subjects: 0
Study 35227777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ew maintenance regimen (integrated population)
Number of subjects: 0
Study 35227777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg eow maintenance regimen (integrated population)
Number of subjects: 0
Study 32275467 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (3 cycles of capecitabine and docetaxel followed by 3 cycles of capecitabine, epirubicin, and cyclophosphamide)
Number of subjects: 585
Study 32275467 — intervention group
Group type: COMPARATOR
Intervention: Control (3 cycles of docetaxel followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 585
Study 32275467 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 585
Study 32275467 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 585
Study 32716040 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based weight loss intervention (12 weeks, self-monitoring via Fitbits, participation in a private Facebook group)
Number of subjects: 55
Study 32716040 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based weight loss intervention
Number of subjects: 55
Study 32756564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (1.9% body mass loss)
Number of subjects: 16
Study 32756564 — intervention group
Group type: COMPARATOR
Intervention: Rehydration protocol (heat tent and fluid replacement)
Number of subjects: 16
Study 35690965 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap balancer (GB) technique
Number of subjects: 94
Study 35690965 — intervention group
Group type: COMPARATOR
Intervention: Measured resection (MR) technique
Number of subjects: 94
Study 33072363 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred and thriving-promoting intervention
Number of subjects: 341
Study 35133549 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 144
Study 35133549 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 144
Study 34433855 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaming at a diameter of 4.0 mm (Group 3) using RIA
Number of subjects: 45
Study 34433855 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaming at a diameter of 1.5 mm (Group 1) using RIA
Number of subjects: 45
Study 34433855 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaming at a diameter of 2.5 mm (Group 2) using RIA
Number of subjects: 45
Study 34433855 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1.5 mm, 2.5 mm, and 4.0 mm)
Number of subjects: 45
Study 32939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26,ZEBOV (Ad26) and MVA-BN-Filo (MVA) vaccines
Number of subjects: 164
Study 32939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous regimens (Ad26,MVA or MVA,Ad26)
Number of subjects: 164
Study 32939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with Ad26 or MVA
Number of subjects: 164
Study 32939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous regimens (Ad26,Ad26)
Number of subjects: 164
Study 32939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous two-dose Ad26,MVA regimens
Number of subjects: 164
Study 32939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 164
Study 34843406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro-CHOP (Romidepsin 12 mg/m² IV on days 1 and 8 of each 3-week cycle for six cycles)
Number of subjects: 421
Study 34843406 — intervention group
Group type: COMPARATOR
Intervention: CHOP (Cyclophosphamide, doxorubicin, vincristine, and prednisone in 3-week cycles for six cycles)
Number of subjects: 421
Study 34843406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro-CHOP
Number of subjects: 421
Study 34843406 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 421
Study 34098994 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment (20 sessions, 5 sessions per week)
Number of subjects: 60
Study 34098994 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment (20 sessions, 5 sessions per week)
Number of subjects: 60
Study 32967450 — intervention group
Group type: EXPERIMENTAL
Intervention: LithoVue
Number of subjects: 50
Study 32967450 — intervention group
Group type: COMPARATOR
Intervention: Uscope PU3022A
Number of subjects: 50
Study 34749994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone 1 mg kg‐1
Number of subjects: 88
Study 34749994 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose dexamethasone 0.3 mg kg‐1
Number of subjects: 88
Study 32634544 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics features from pretreatment 18F-DOPA PET imaging
Number of subjects: 86
Study 32634544 — intervention group
Group type: COMPARATOR
Intervention: Patients with unknown MGMT methylation status
Number of subjects: 86
Study 34609284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 220
Study 34609284 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system based on regression coefficients
Number of subjects: 220
Study 34824001 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and lumbar segmental stabilization
Number of subjects: 70
Study 34824001 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and lumbar segmental stabilization plus specific hip strengthening
Number of subjects: 70
Study 35057413 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 10
Study 35057413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 35015038 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week anticoagulant therapy (n=207)
Number of subjects: 417
Study 35015038 — intervention group
Group type: COMPARATOR
Intervention: 3-month anticoagulant therapy (n=210)
Number of subjects: 417
Study 35373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Local-SC catchment areas
Number of subjects: 20603
Study 33713371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexamethasone (0.2% ropivacaine plus 0.025% dexamethasone)
Number of subjects: 80
Study 33713371 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (0.2% ropivacaine)
Number of subjects: 80
Study 35817072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tixagevimab-cilgavimab
Number of subjects: 1417
Study 33731163 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern medicine (pirfenidone) plus TCM
Number of subjects: 0
Study 33731163 — intervention group
Group type: COMPARATOR
Intervention: Modern medicine plus TCM placebo
Number of subjects: 0
Study 32546491 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation programme plus TYMO system
Number of subjects: 195
Study 32546491 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation programme plus Walker View
Number of subjects: 195
Study 32546491 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation programme
Number of subjects: 195
Study 616973594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cabergoline (0.5 g weekly) and metformin (1000 mg daily) for 3 months
Number of subjects: 250
Study 616973594 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg daily) and placebo for 3 months
Number of subjects: 250
Study 33602710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed exercise regimen
Number of subjects: 380
Study 33602710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid (HOCl) wound solution
Number of subjects: 380
Study 33602710 — intervention group
Group type: COMPARATOR
Intervention: Placebo wound solution
Number of subjects: 380
Study 33602710 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 380
Study 32282434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intacs and CXL (same session)
Number of subjects: 150
Study 32282434 — intervention group
Group type: COMPARATOR
Intervention: Intacs followed by CXL (3 months later)
Number of subjects: 150
Study 35686506 — intervention group
Group type: COMPARATOR
Intervention: Malaysian participants
Number of subjects: 353
Study 35686506 — intervention group
Group type: EXPERIMENTAL
Intervention: ANZ participants
Number of subjects: 353
Study 33864830 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA+SFC (100 and 115 mg/day)
Number of subjects: 15
Study 33864830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CNT)
Number of subjects: 15
Study 32762882 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐ IFNα (180 mcg/week) with TDF (300 mg/day)
Number of subjects: 67
Study 32762882 — intervention group
Group type: COMPARATOR
Intervention: TDF (300 mg/day)
Number of subjects: 67
Study 32762882 — intervention group
Group type: COMPARATOR
Intervention: Peg‐ IFNα (180 mcg/week)
Number of subjects: 67
Study 32762882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Peg‐ IFNα and TDF)
Number of subjects: 67
Study 32762882 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with Peg‐IFNα
Number of subjects: 67
Study 32762882 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with TDF
Number of subjects: 67
Study 35610142 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally applied estrogen (LET)
Number of subjects: 120
Study 35610142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34174455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PtDA)
Number of subjects: 193
Study 34174455 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 193
Study 34174455 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated patients
Number of subjects: 193
Study 33896436 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Family Problem-Solving Therapy (OFPST)
Number of subjects: 274
Study 33896436 — intervention group
Group type: COMPARATOR
Intervention: Control group (internet resource comparison)
Number of subjects: 274
Study 32873678 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S)
Number of subjects: 183
Study 32873678 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 183
Study 32873678 — intervention group
Group type: EXPERIMENTAL
Intervention: SADI-S
Number of subjects: 183